Ranbaxy Laboratories and its new owner Japan’s Daiichi Sankyo, which now holds 63.92% of Ranbaxy’s equity share capital, reconstituted a new 10-member panel.
From the company’s earlier 15 member panel, the company retained only three members including former owner Malvinder Singh, COO Atul Sobti and Religare CEO & MD Sunil Godhwani.
The newly announced board reflects the changed ownership structure at Ranbaxy, following Daiichi Sankyo’s strategic investment during the last month (Nov 2008).
The largest Indian drug maker, in terms of market value, Sun Pharmaceutical Industries Ltd has started initiatives to end acquisition dispute of Taro Pharmaceutical Industries Ltd. The company has offered to raise purchase price of stake to close the deal out of court. 
The US Food and Drug Administration (FDA) can take more time to approve Ranbaxy's generic version of GSK's anti-migraine medicine, Imitrex. The delay may cause potential loss of Rs 300 crore to the drug major. Research Analyst Ranjit Kapadia said, "Since, Ranbaxy has not been able to launch the drug in the US and patent for the drug is also going to expire in February 2009, the company may have to suffer a potential revenue loss of Rs 240-250 crore in the current year." 
Pharmaceutical company Strides Acrolab has announced receipt of two ANDA approvals for Sterile vancomycin in HCL USP 500mg and 1g per vial and sterile Vancomycin HCI USP 5g per vial pharmacy bulk package. 
Piramal Healthcare has acquired New York-based Minrad International, a manufacturer of generic inhalation anaesthetic drugs for $40 million. 
Aurobindo Pharma, an Indian private pharmaceutical company, informed that it has got tentative sanction from US Food & Drug Administration (USFDA) to make and sell fixed dosed combination Abacavir Sulfate/ Lamivudine Tablets.
